NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,412−0.30%BTC$81,228−0.01%VIX14.81−4.08%live tape · as of 05:00 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic
Haleon plc ADR
HLN · the NYSE · USD · Market cap $40.4B · 24,535 employees
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the As…
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price9.19 USD
Fair value13.06
Ethical score70.0/100
Our investment reviews on this name
2026-09-01Read Accumulation10.18-9.7% to today
2026-08-01Read Markup9.94-7.5% to today
2026-07-02Read Distribution9.13+0.7% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Haleon plc ADR holds its Distribution at $9.19. The statistical read favours the buyers, held for 69 days.
As held on the ledger · 2026-09-11
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 69 days
Price at the screen
$9.19
Valuation
18.76 trailing · 14.73 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.25
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
26.31%
Below 33%
Interest-bearing debt is just 26.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
8.89%
Below 49%
Money owed to the company is 8.9% of assets, under the 49% limit.
Pass
Revenue purity
0.52%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 42.2% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits +35% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Daily Remedies Rarely Deliver Strong Growth
Walk into any pharmacy and you will see Haleon products on the shelf. Oral health, vitamins and pain relief sit in a crowded market where brands matter but pricing power stays limited. With revenue growth stuck at 1 percent, a narrow moat and return on equity of just 10 percent, the business shows steady cash flow yet little spark to justify an investment case.
Forward earnings sit at 16.6 times while the shares trade at a 24 percent discount to our fair value. That gap looks attractive on paper, yet our opportunity rating remains none because low single-digit growth and modest returns on capital rarely compound into meaningful outperformance over time.
Currency moves, retailer pressure on prices and the risk that slow top-line trends persist all weigh on the outlook. Ethical screens are cleared, but the numbers still point to a pass. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HLN trades on the NYSE (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (5 analysts) rates it buy, with a mean price target of $12.
2026-08-01Markup · changed$9.94+8.9%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (5 analysts) rates it buy, with a mean price target of $12.
2026-07-18Distribution$9.13+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 15%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (5 analysts) rates it buy, with a mean price target of $12.
2026-07-03Distribution$9.13+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$9.13Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.